Evidence map›Paper›PMID 34687693›Full record

ArticleThe Journal of pediatrics2022

Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension.

Megan Griffiths, Jun Yang, Dhananjay Vaidya, Melanie Nies, Stephanie Brandal, D Dunbar Ivy, Francis Hickey, Kristine Wolter-Warmerdam, Eric D Austin, Mary Mullen and 7 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 1 country.

Megan GriffithsDivision of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD; Department of Internal Medicine, Johns Hopkins University, Baltimore, MD.
Jun YangDivision of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD.
Dhananjay VaidyaDivision of Pediatric Cardiology, Children's Hospital Colorado, Aurora, CO.
Melanie NiesDivision of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD.
Stephanie BrandalDivision of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD.
D Dunbar IvyDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, CO.
Francis HickeySie Center for Down Syndrome, Children's Hospital Colorado, Aurora, CO.
Kristine Wolter-WarmerdamDivision of Allergy, Immunology, and Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN.
Eric D AustinDepartment of Cardiology, Boston Children's Hospital, Boston, MA.
Mary MullenDivision of Human Genetics, Cincinnati Children's Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Michael W PauciuloDivision of Pediatric Cardiology; Department of Pediatrics, Columbia University, New York, NY.
Katie A LutzDivision of Pediatric Cardiology; Department of Pediatrics, Columbia University, New York, NY.
Erika B RosenzweigDepartment of Internal Medicine, Johns Hopkins University, Baltimore, MD.
Russel HirschDivision of Pediatric Cardiology, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH.
Delphine YungDivision of Pediatric Cardiology, Department of Pediatrics, University of Washington, Seattle, WA.
William C NicholsDivision of Pediatric Cardiology; Department of Pediatrics, Columbia University, New York, NY.
Allen D EverettDivision of Pediatric Cardiology, Department of Pediatrics, Johns Hopkins University, Baltimore, MD. Electronic address: aeveret3@jhmi.edu.
Johns Hopkins University · USColumbia University Irving Medical Center · USUniversity of Colorado Denver · USBoston Children's Hospital · USChildren's Hospital Colorado · USUniversity of Cincinnati · USUniversity of Cincinnati Medical Center · USUniversity of Washington · USVanderbilt University Medical Center · US

Funding

NIH Prior Approval Process ProfessionalUL1TR002535 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2018 to 2022
$51.1M
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1M
National Biological Sample and Data Repository for PAHR24HL105333 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI NICHOLS, WILLIAM C · 2012 to 2016
$10.1M
Clinical and mechanistic role of HDGF in pulmonary hypertensionR01HL135114 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI EVERETT, ALLEN D · 2017 to 2020
$2.9M
Role of IGF axis in pulmonary hypertensionR01HL150070 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI EVERETT, ALLEN D, YANG, JUN · 2020 to 2023
$2.8M
NCATS NIH HHS UL1 TR002535NHLBI NIH HHS R01 HL135114NHLBI NIH HHS R01 HL150070NHLBI NIH HHS R24 HL105333NICHD NIH HHS K12 HD000850
6 · The paper itself

Abstract

objectiveTo evaluate the performance of pulmonary hypertension (PH) biomarkers in children with Down syndrome, an independent risk factor for PH, in whom biomarker performance may differ compared with other populations. STUDY

designSerum endostatin, interleukin (IL)-1 receptor 1 (ST2), galectin-3, N-terminal pro hormone B-natriuretic peptide (NT-proBNP), IL-6, and hepatoma-derived growth factor (HDGF) were measured in subjects with Down syndrome and PH (n = 29), subjects with Down syndrome and resolved PH (n = 13), subjects with Down syndrome without PH (n = 49), and subjects without Down syndrome with World Symposium on Pulmonary Hypertension group I pulmonary arterial hypertension (no Down syndrome PH group; n = 173). Each biomarker was assessed to discriminate PH in Down syndrome. A classification tree was created to distinguish PH from resolved PH and no PH in children with Down syndrome.

resultsEndostatin, galectin-3, HDGF, and ST2 were elevated in subjects with Down syndrome regardless of PH status. Not all markers differed between subjects with Down syndrome and PH and subjects with Down syndrome and resolved PH. NT-proBNP and IL-6 levels were similar in the Down syndrome with PH group and the no Down syndrome PH group. A classification tree identified NT-proBNP and galectin-3 as the best markers for sequentially distinguishing PH, resolved PH, and no PH in subjects with Down syndrome.

conclusionsProteomic markers are used to improve the diagnosis and prognosis of PH but, as demonstrated here, can be altered in genetically unique populations such as individuals with Down syndrome. This further suggests that clinical biomarkers should be evaluated in unique groups with the development of population-specific nomograms.

Indexed as

AdolescentBiomarkersCase-Control StudiesChildChild, PreschoolDown SyndromeEndostatinsFemaleGalectin 3HumansHypertension, PulmonaryIntercellular Signaling Peptides and ProteinsInterleukin-6MaleNatriuretic Peptide, BrainPeptide FragmentsBiomarkersEndostatinsGalectin 3hepatoma-derived growth factorIntercellular Signaling Peptides and ProteinsInterleukin-6Natriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Receptors, Interleukin-1

Identifiers

PMID34687693
PMCPMC9092284
OpenAlexW3209960858

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.